Proline-Rich Polypeptide Complex for BDNF Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current infant milk formulas are insufficient for proper development and maintenance of the immune and nervous systems, and there is a need for safe, standardized biological agents that can stimulate these systems effectively in both adults and children.
Innovation Solution
The use of a Proline-Rich Polypeptide complex derived from mammalian colostrum, specifically isolated from bovine colostrum, which is administered at specific dosages to enhance BDNF levels and provide immunotropic and neuroprotective effects, formulated into various pharmaceutical and nutritional products for systemic administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If infant milk formulas are used for feeding, then basic nutritional needs are met, but proper development and maintenance of the immune and nervous systems is insufficient
Solution Approach 1:
The patent extracts and isolates specific biologically active components (proline-rich polypeptides) from mammalian colostrum to create a concentrated supplement. This extraction principle allows the formulation to deliver high concentrations of immune-supporting and neuroprotective factors that are insufficient in regular infant milk formulas, directly addressing the contradiction between basic nutrition and adequate bioactive substance delivery.
Solution Approach 2:
The patent creates a composite nutritional formulation by combining proline-rich polypeptides from colostrum with infant milk formula. This composite approach integrates the benefits of standard formula nutrition with the enhanced immune and nervous system support provided by colostrum-derived polypeptides, resolving the contradiction by merging basic nutrition with targeted bioactive supplementation.
2Reliability
If standardized biological agents are used to stimulate immune and nervous systems, then therapeutic effects are achieved, but safety and standardization challenges arise
Solution Approach 1:
The patent applies parameter changes by establishing specific concentration ranges for proline-rich polypeptides (0.1-10 mg/mL) and defining precise manufacturing parameters for colostrum collection and processing. These standardized parameters ensure consistent therapeutic effects across different batches while maintaining safety, directly addressing the contradiction between reliable therapeutic delivery and formulation standardization complexity.
3Reliability
If BDNF levels are increased through PRP administration, then cognitive functions and neuroprotection are improved, but dosage optimization and potential side effects must be managed
Solution Approach 1:
The patent employs partial action by administering proline-rich polypeptides at optimized sub-therapeutic doses (0.1-10 mg/mL) that sufficiently stimulate BDNF production and cognitive function without risking overdose effects. This partial dosing strategy achieves the desired neuroprotective and cognitive benefits while maintaining safety and ease of administration, resolving the contradiction between reliable cognitive improvement and simple dosage management.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The invention relates to the Proline-Rich Polypeptide complex (PRP) derived from the mammalian colostrum for use in the treatment of the disorders and conditions related to the alterations of the Brain-Derived Neurotrophic Factor level as well as modulation thereof, particularly disorders and conditions wherein therapeutic strategy is based on the increasing of the BDNF concentration in blood. The PRP complex is postulated to be used for nutrition of adults, young children/babies and infants to promote and preserve the proper development and function of both immune and nervous system. PRPs may be used for supplementation of modified milk and infant milk formulae to make it closer to breast milk.